gefitinib has been researched along with Atrophy in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Demehri, FR; Dempsey, PJ; Feng, Y; Freeman, JJ; Teitelbaum, DH | 1 |
Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS | 1 |
2 other study(ies) available for gefitinib and Atrophy
Article | Year |
---|---|
TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways.
Topics: Animals; Apoptosis; Atrophy; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interferon-gamma; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parenteral Nutrition, Total; Quinazolines; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; ErbB Receptors; Female; Gefitinib; Glucagon-Like Peptide 2; Intestines; Mice; Mice, Inbred C57BL; Organ Size; Quinazolines | 2007 |